Abbreviations: AITL = angioimmunoblastic T-cell lymphoma; MAC = myeloablative conditioning; MF = mycosis fungoides; NRM = nonrelapse mortality; PTCL = peripheral T-cell lymphoma; RD = refractory disease; RIC = reduced-intensity conditioning.
Peripheral T-cell lymphomas form a heterogeneous group of poorprognosis hematological malignancies representing 10-15% of all lymphomas. Angioimmunoblastic T-cell lymphoma (AITL) is a subtype defined by follicular helper T-cell proliferation. AITL carries a particularly poor prognosis. Chemotherapy-based treatment (usually a CHOP-like regimen) yields a response rate of~60%, but long-term disease-free survival (DFS) only reaches~20%. Kyriakou et al. 1 reported a series of 146 AITL patients treated with autologous hematopoietic SCT (HSCT): the OS rate at 4 years was 59% but the 2-year cumulative incidence of relapse was 40%. Indirect evidence points to a graft-versus-lymphoma (GVL) effect after allo-HSCT for peripheral T-cell lymphoma (PTCL; summarized in Table 1 ). Most chemoresistant patients relapse after auto-SCT, whereas allo-SCT can provide long-term DFS in a substantial number of cases. In a recent large study, 2 13 patients with stable disease, progressive disease (PD) or refractory disease before allotransplantation had a CR after allo-HSCT with myeloablative conditioning, with a median 5-year OS of 29%. Similar results were obtained after reduced-intensity conditioning allo-SCT in 17 patients who were allografted for relapsed or refractory PTCL. 3 Another argument in favor of a GVL effect is the poor efficacy of T-depleted transplantation: Duarte et al. 4 reported 2-year PFS rates of 17% after ex vivo T-cell-depleted allo-HSCT and 39% after T-cellrepleted allo-HSCT.
Interestingly, the occurrence of GVHD was also associated with a better outcome. 5, 6 On the basis of the hypothesis that allogeneic donor T cells can eliminate residual recipient malignant lymphoid cells, DLI may have a place in the therapeutic arsenal after allo-SCT. However, few data are available on the effect of DLI on relapse after allo-HSCT, especially for lymphomas. Regarding B-cell lymphomas, better responses to DLI are reported in indolent lymphomas than in aggressive lymphoma subtypes, highlighting the complexity of the immune reaction. A similar allogeneic effect against autoreactive host lymphocytes has also been suggested in autoimmune diseases, especially autoimmune cytopenias. 7 In Dodero's study, 8 three CR and three PR cases were obtained after DLI in 12 patients with T-cell lymphomas who relapsed after allo-HSCT, but 5 of them had received salvage chemotherapy before DLI. In another large cohort, patients who received DLI both had a sustained second CR. 2 Coradini 3 treated three patients with DLI for PD after allo-HSCT, obtaining one PR and one CR. Neither report mentioned concomitant or prior chemotherapy. Finally, regression of extranodal relapse after CsA tapering has been reported in two patients. 9, 10 Here, we report the first observation clearly supporting an allogeneic effect on nodal relapse after allo-HSCT for AITL. A 56-year-old man presented in July 2008 with asthenia, weight loss, fever, night sweats and polyadenopathy. Blood analyses showed lactate dehydrogenase (LDH) elevation and polyclonal hypergammaglobulinemia. Histological analysis of a cervical node biopsy specimen showed morphologic and immunophenotypic characteristics of AITL. Serological tests for HIV and hepatitis C and B viruses were negative. Computed tomography (CT) revealed enlarged mediastinal, abdominal and retroperitonal lymph nodes, splenomegaly and bilateral pulmonary abnormalities. BM biopsy showed no malignant involvement. Stage IV lymphoma (Ann Arbor classification) with extranodular involvement was diagnosed. The patient received six cycles of the CHOP regimen combined with alemtuzumab. The disease was chemosensitive. . GVHD prophylaxis consisted of CsA and mycophenolate mofetil, the latter being discontinued on day +28. On day +100 the patient showed good hematological recovery and 100% donor chimerism, but he developed fever, asthenia, and elevated C-reactive protein and LDH levels. A repeat CT showed lymph node enlargement to 4 cm, as compared with 2 cm before the graft. PET revealed a significant increase in the metabolic activity of the involved mediastinal nodes (SUV max 7), suggesting disease progression (Figure 1a) . CsA was rapidly tapered and discontinued on day +130. On day +160 after allo-HSCT, PET showed a fall in metabolic activity, suggesting a GVL effect. One month after CsA withdrawal he developed an extensive skin rash and febrile cough. We found no evidence of an infectious process by bronchoscopy with bronchoalveolar lavage, leading to a diagnosis of pulmonary and grade 3 cutaneous GVHD. CT performed before initiating corticosteroid therapy confirmed significant shrinkage of the mediastinal nodes (1.5 cm, compared with 4 cm at post-transplant relapse). A third PET/CT scan performed 2 weeks later showed no pathological metabolic activity (Figure 1b) . GVHD was successfully controlled with corticosteroids (2 mg/kg) and CsA. The GVHD became chronic, affecting the skin, mucosae and eyes, and requiring low-dose CsA. Corticosteroids were slowly tapered and withdrawn 26 months post transplant. The patient made a good clinical recovery, apart from moderate chronic GVHD. No evidence of disease activity was found on control PET scans 33 months post transplant.
This case strongly suggests an allogeneic effect on nodal relapse after allo-HSCT. No chemotherapy or corticosteroids were administered before the response, which was thus induced by CsA tapering and the subsequent occurrence of chronic GVHD.
In conclusion, as a first-line treatment, both auto-and allo-HSCT seem to provide encouraging results in peripheral T-cell lymphoma, and the available retrospective data do not show a clear advantage of one strategy over the other. A prospective clinical trial is currently addressing this question. Nevertheless, as illustrated by this patient's case, there is very likely a GVL effect in this setting, suggesting that 'aggressive' immunomodulation after allo-HSCT (DLI or early tapering of immunosuppressive drugs) may be warranted for high-risk patients. Allo-HSCT may prove to be a curative treatment for chemoresistant PTCL and for relapsed pTCL after auto-HSCT. 
